Sansure Biotech Future Growth
Future criteria checks 5/6
Sansure Biotech is forecast to grow earnings and revenue by 34.2% and 26% per annum respectively. EPS is expected to grow by 34.3% per annum. Return on equity is forecast to be 6.7% in 3 years.
Key information
34.2%
Earnings growth rate
34.3%
EPS growth rate
Medical Equipment earnings growth | 26.5% |
Revenue growth rate | 26.0% |
Future return on equity | 6.7% |
Analyst coverage | Low |
Last updated | 30 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,468 | 581 | N/A | 204 | 1 |
12/31/2025 | 2,009 | 448 | N/A | 121 | 1 |
12/31/2024 | 1,496 | 323 | N/A | -108 | 1 |
9/30/2024 | 1,407 | 259 | -150 | 203 | N/A |
6/30/2024 | 1,296 | 429 | -236 | 97 | N/A |
3/31/2024 | 1,203 | 385 | -299 | 36 | N/A |
12/31/2023 | 1,007 | 364 | -348 | 44 | N/A |
9/30/2023 | 3,015 | 638 | 617 | 1,161 | N/A |
6/30/2023 | 4,188 | 904 | 973 | 1,523 | N/A |
3/31/2023 | 5,206 | 1,345 | 1,387 | 1,890 | N/A |
12/31/2022 | 6,450 | 1,937 | 2,000 | 2,559 | N/A |
9/30/2022 | 5,316 | 2,084 | 1,255 | 1,673 | N/A |
6/30/2022 | 5,176 | 2,247 | 1,551 | 1,963 | N/A |
3/31/2022 | 4,791 | 2,272 | 1,633 | 2,121 | N/A |
12/31/2021 | 4,515 | 2,243 | 1,504 | 1,877 | N/A |
9/30/2021 | 4,425 | 2,361 | 2,050 | 2,316 | N/A |
6/30/2021 | 4,691 | 2,506 | 2,175 | 2,404 | N/A |
3/31/2021 | 5,526 | 3,046 | 2,668 | 2,801 | N/A |
12/31/2020 | 4,763 | 2,617 | 2,534 | 2,642 | N/A |
9/30/2020 | 3,727 | 2,034 | 1,781 | 1,830 | N/A |
6/30/2020 | 2,299 | 1,263 | 1,097 | 1,150 | N/A |
3/31/2020 | 683 | 233 | 170 | 203 | N/A |
12/31/2019 | 365 | 39 | -12 | 22 | N/A |
12/31/2018 | 303 | 7 | -23 | 10 | N/A |
12/31/2017 | 225 | -11 | N/A | -61 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688289's forecast earnings growth (34.2% per year) is above the savings rate (2.8%).
Earnings vs Market: 688289's earnings (34.2% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 688289's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688289's revenue (26% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688289's revenue (26% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688289's Return on Equity is forecast to be low in 3 years time (6.7%).